CN108367006B - 用于治疗血液癌症的赛度替尼 - Google Patents

用于治疗血液癌症的赛度替尼 Download PDF

Info

Publication number
CN108367006B
CN108367006B CN201680073276.XA CN201680073276A CN108367006B CN 108367006 B CN108367006 B CN 108367006B CN 201680073276 A CN201680073276 A CN 201680073276A CN 108367006 B CN108367006 B CN 108367006B
Authority
CN
China
Prior art keywords
cerdulatinib
patient
pharmaceutically acceptable
lymphoma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680073276.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN108367006A (zh
Inventor
格雷戈里·科菲
冯佳佳
安德鲁·斯蒂尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CN108367006A publication Critical patent/CN108367006A/zh
Application granted granted Critical
Publication of CN108367006B publication Critical patent/CN108367006B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680073276.XA 2015-12-04 2016-12-02 用于治疗血液癌症的赛度替尼 Active CN108367006B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562263582P 2015-12-04 2015-12-04
US62/263,582 2015-12-04
US201662342727P 2016-05-27 2016-05-27
US201662342755P 2016-05-27 2016-05-27
US62/342,755 2016-05-27
US62/342,727 2016-05-27
US201662371145P 2016-08-04 2016-08-04
US62/371,145 2016-08-04
PCT/US2016/064824 WO2017096303A2 (en) 2015-12-04 2016-12-02 Cerdulatinib for treating hematological cancers

Publications (2)

Publication Number Publication Date
CN108367006A CN108367006A (zh) 2018-08-03
CN108367006B true CN108367006B (zh) 2021-12-31

Family

ID=57614468

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073276.XA Active CN108367006B (zh) 2015-12-04 2016-12-02 用于治疗血液癌症的赛度替尼

Country Status (8)

Country Link
US (2) US10736895B2 (enExample)
EP (1) EP3383396B1 (enExample)
JP (1) JP6944936B2 (enExample)
CN (1) CN108367006B (enExample)
AU (1) AU2016363005A1 (enExample)
CA (1) CA2950640A1 (enExample)
ES (1) ES2959692T3 (enExample)
WO (1) WO2017096303A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196385A1 (en) 2015-05-29 2016-12-08 Portola Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
ES2913119T3 (es) 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
BR112020013976A2 (pt) * 2018-01-09 2020-12-08 Dermavant Sciences GmbH Composições farmacêuticas para pele tópicas que contêm cerdulatinibe e usos das mesmas
KR20210003789A (ko) * 2018-05-04 2021-01-12 포톨라 파마슈티컬스, 인코포레이티드 림프종을 치료하는 방법
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
US20200262925A1 (en) * 2019-02-15 2020-08-20 Janssen Biotech, Inc. Combination Therapy For Treatment Of B-Cell Malignancies
WO2021242614A1 (en) * 2020-05-26 2021-12-02 Alexion Pharmaceuticals, Inc. Circulating b cell subpopulations in indolent b cell lymphoma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401312T1 (de) 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2373226T3 (es) 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
CA2723205C (en) 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010129802A1 (en) 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
ES2546294T7 (es) 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
US20110130415A1 (en) 2009-12-01 2011-06-02 Rajinder Singh Protein kinase c inhibitors and uses thereof
US9398308B2 (en) 2010-07-28 2016-07-19 Qualcomm Incorporated Coding motion prediction direction in video coding
WO2012045020A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016196385A1 (en) 2015-05-29 2016-12-08 Portola Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
ES2913119T3 (es) 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Phase I Open-Label，Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies;PATEL MANISH ET AL;《BLOOD》;20141231;摘要 *
BLUNT MATTHEW D ET AL.The Syk\Jak Inhibitor Cerdulatinib(PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling.《BLOOD》.2015,摘要. *
Cerdulatinib，a novel dual SYK/JAK kinase inhibitor，has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma;MA JIAO ET AL:;《ONCOTARGET》;20140609;摘要，讨论 *
The Syk\Jak Inhibitor Cerdulatinib(PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling;BLUNT MATTHEW D ET AL;《BLOOD》;20151203;摘要 *

Also Published As

Publication number Publication date
CN108367006A (zh) 2018-08-03
WO2017096303A2 (en) 2017-06-08
CA2950640A1 (en) 2017-06-04
ES2959692T3 (es) 2024-02-27
US20180353506A1 (en) 2018-12-13
US11446300B2 (en) 2022-09-20
EP3383396A2 (en) 2018-10-10
WO2017096303A3 (en) 2017-08-03
US20210000827A1 (en) 2021-01-07
EP3383396B1 (en) 2023-07-12
JP2018535996A (ja) 2018-12-06
JP6944936B2 (ja) 2021-10-06
AU2016363005A1 (en) 2018-07-05
US10736895B2 (en) 2020-08-11

Similar Documents

Publication Publication Date Title
US11446300B2 (en) Cerdulatinib for treating hematological cancers
US12350269B2 (en) Cerdulatinib for the treatment of b-cell malignancies
JP7323592B2 (ja) 癌を治療するための併用療法
CN106659716A (zh) 阿吡莫德组合物及其使用方法
KR102849513B1 (ko) 암 치료 방법
CN114828842A (zh) 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
Pilehvari et al. The role of genetics and synergistic effect of targeting common genetic mutations in acute lymphoblastic leukemia (ALL)
HK1262118B (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK1262118A1 (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK40061501A (en) Combination therapy for treating cancer
HK1253804B (en) Cerdulatinib for the treatment of b-cell malignancies
HK1253804A1 (en) Cerdulatinib for the treatment of b-cell malignancies
Puvvada et al. Emerging Frontiers in Therapeutics of Diffuse Large B Cell Lymphoma: Epigenetics and B Cell Receptor Signaling
HK1229709B (en) Combination therapy for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant